Ceruloplasmin and Coronary Heart Disease-A Systematic Review
Several studies indicate that oxidative stress might play a central role in the initiation and maintenance of cardiovascular diseases. It remains unclear whether ceruloplasmin acts as a passive marker of inflammation or as a causal mediator. To better understand the impact of ceruloplasmin blood levels on the risk of cardiovascular disease, and paying special attention to coronary heart disease, we conducted a search on the two most commonly used electronic databases (Medline via PubMed and EMBASE) to analyze current assessment using observational studies in the general adult population. Each study was quality rated using criteria developed by the US Preventive Services Task Force. Most of 18 eligible studies reviewed support a direct relationship between ceruloplasmin elevated levels and incidence of coronary heart disease. Our results highlight the importance of promoting clinical trials that determine the functions of ceruloplasmin as a mediator in the development of coronary heart disease and evaluate whether the treatment of elevated ceruloplasmin levels has a role in the prognosis or prevention of this condition.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Nutrients - 12(2020), 10 vom: 21. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arenas de Larriva, Antonio P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Ceruloplasmin |
|---|
| Anmerkungen: |
Date Completed 05.04.2021 Date Revised 05.04.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/nu12103219 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316657123 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316657123 | ||
| 003 | DE-627 | ||
| 005 | 20231225161549.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/nu12103219 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1055.xml |
| 035 | |a (DE-627)NLM316657123 | ||
| 035 | |a (NLM)33096845 | ||
| 035 | |a (PII)E3219 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arenas de Larriva, Antonio P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ceruloplasmin and Coronary Heart Disease-A Systematic Review |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.04.2021 | ||
| 500 | |a Date Revised 05.04.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Several studies indicate that oxidative stress might play a central role in the initiation and maintenance of cardiovascular diseases. It remains unclear whether ceruloplasmin acts as a passive marker of inflammation or as a causal mediator. To better understand the impact of ceruloplasmin blood levels on the risk of cardiovascular disease, and paying special attention to coronary heart disease, we conducted a search on the two most commonly used electronic databases (Medline via PubMed and EMBASE) to analyze current assessment using observational studies in the general adult population. Each study was quality rated using criteria developed by the US Preventive Services Task Force. Most of 18 eligible studies reviewed support a direct relationship between ceruloplasmin elevated levels and incidence of coronary heart disease. Our results highlight the importance of promoting clinical trials that determine the functions of ceruloplasmin as a mediator in the development of coronary heart disease and evaluate whether the treatment of elevated ceruloplasmin levels has a role in the prognosis or prevention of this condition | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a ceruloplasmin | |
| 650 | 4 | |a coronary heart disease | |
| 650 | 4 | |a inflammation | |
| 650 | 7 | |a Ceruloplasmin |2 NLM | |
| 650 | 7 | |a EC 1.16.3.1 |2 NLM | |
| 700 | 1 | |a Limia-Pérez, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Alcalá-Díaz, Juan F |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso, Alvaro |e verfasserin |4 aut | |
| 700 | 1 | |a López-Miranda, José |e verfasserin |4 aut | |
| 700 | 1 | |a Delgado-Lista, Javier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nutrients |d 2009 |g 12(2020), 10 vom: 21. Okt. |w (DE-627)NLM206140738 |x 2072-6643 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:10 |g day:21 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/nu12103219 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2020 |e 10 |b 21 |c 10 | ||